TrialNature communications2025

Neoadjuvant tislelizumab with afatinib for locally advanced head and neck squamous cell carcinoma (neoCHANCE-1): a phase 2 clinical trial.

Zhi-Gong Wei et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.